Literature DB >> 23302653

Optimized protocol for amyloid-β extraction from the brain.

María Izco1, Pedro Pesini, Virginia Pérez-Grijalba, Noelia Fandos, Manuel Sarasa.   

Abstract

Brain levels of amyloid-β (Aβ) are frequently assessed in transgenic mice models of Alzheimer's disease. The procedure involves tissue sample homogenization using different buffers in a sequential process. No attempt has been made to assess if these procedures are able to extract the total amount of Aβ present in the samples. Here we present data suggesting that standard protocols can lead to a dramatic underestimation of the Aβ content. Results show that higher extraction buffer volumes and at least two repetitions of the soluble and membrane-bound extraction steps are necessary for a more accurate estimation of the Aβ content in brain tissues.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23302653     DOI: 10.3233/JAD-121798

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  6 in total

Review 1.  Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling.

Authors:  Sunil S Adav; Siu Kwan Sze
Journal:  Mol Brain       Date:  2016-11-03       Impact factor: 4.041

2.  Dementia-linked amyloidosis is associated with brain protein deamidation as revealed by proteomic profiling of human brain tissues.

Authors:  Sunil S Adav; Xavier Gallart-Palau; Kok Hian Tan; Sai Kiang Lim; James P Tam; Siu Kwan Sze
Journal:  Mol Brain       Date:  2016-02-19       Impact factor: 4.041

3.  Human amyloid-β enriched extracts: evaluation of in vitro and in vivo internalization and molecular characterization.

Authors:  Cristina M Pedrero-Prieto; Alicia Flores-Cuadrado; Daniel Saiz-Sánchez; Isabel Úbeda-Bañón; Javier Frontiñán-Rubio; Francisco J Alcaín; Lourdes Mateos-Hernández; José de la Fuente; Mario Durán-Prado; Margarita Villar; Alino Martínez-Marcos; Juan R Peinado
Journal:  Alzheimers Res Ther       Date:  2019-06-29       Impact factor: 6.982

4.  Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice.

Authors:  Yanhong Wang; Yuzhu Hong; Jiyu Yan; Breanna Brown; Xiaoyang Lin; Xiaolin Zhang; Ning Shen; Minghua Li; Jianfeng Cai; Marcia Gordon; David Morgan; Qingyu Zhou; Chuanhai Cao
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

5.  The Memory Benefit to Aged APP/PS1 Mice from Long-Term Intranasal Treatment of Low-Dose THC.

Authors:  Oksana Fihurka; Yuzhu Hong; Jiyu Yan; Breanna Brown; Xiaoyang Lin; Ning Shen; Yanhong Wang; Haohan Zhao; Marcia N Gordon; David Morgan; Qingyu Zhou; Ping Chang; Chuanhai Cao
Journal:  Int J Mol Sci       Date:  2022-04-12       Impact factor: 6.208

6.  Altered basal forebrain function during whole-brain network activity at pre- and early-plaque stages of Alzheimer's disease in TgF344-AD rats.

Authors:  Georgios A Keliris; Marleen Verhoye; Monica van den Berg; Mohit H Adhikari; Marlies Verschuuren; Isabel Pintelon; Tamara Vasilkovska; Johan Van Audekerke; Stephan Missault; Loran Heymans; Peter Ponsaerts; Winnok H De Vos; Annemie Van der Linden
Journal:  Alzheimers Res Ther       Date:  2022-10-10       Impact factor: 8.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.